Cancers, Vol. 13, Pages 1920: The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Cancers, Vol. 13, Pages 1920: The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Cancers doi: 10.3390/cancers13081920
Authors:
Ruben Van Dijck
Jeanette K. Doorduijn
Jacoline E.C. Bromberg
Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
Source: Cancers - Category: Cancer & Oncology Authors: Ruben Van Dijck Jeanette K. Doorduijn Jacoline E.C. Bromberg Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lymphoma | Methotrexate | Non-Hodgkin's Lymphoma | Primary CNS Lymphoma | Rituxan